Human epidermal growth factor receptor-2 (HER2), also known as HER2/erbB2, is a tumor-associated antigen that is over-expressed in ~ 10–20% of breast cancer cases, ~ 3% of cervical and uterine cancer cases [5], and ~ 27.6% of ovarian cancer cases [6]. This evidence concerns the gene ERBB2 and uterine cancer.